NRx Pharmaceuticals’ (NRXP) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reiterated their buy rating on shares of NRx Pharmaceuticals (NASDAQ:NRXP) in a research report report published on Monday,Benzinga reports. They currently have a $31.00 price target on the stock.

Several other equities analysts have also weighed in on NRXP. HC Wainwright reiterated a “buy” rating and issued a $19.00 target price on shares of NRx Pharmaceuticals in a report on Friday. Ascendiant Capital Markets boosted their price target on shares of NRx Pharmaceuticals from $44.00 to $45.00 and gave the company a “buy” rating in a research note on Monday, December 2nd.

NRx Pharmaceuticals Price Performance

NASDAQ:NRXP opened at $2.05 on Monday. The firm has a market capitalization of $34.68 million, a price-to-earnings ratio of -0.96 and a beta of 1.22. The company’s 50-day moving average is $2.99 and its two-hundred day moving average is $2.02. NRx Pharmaceuticals has a 1-year low of $1.10 and a 1-year high of $6.01.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its earnings results on Friday, March 14th. The company reported ($0.30) earnings per share for the quarter, missing the consensus estimate of ($0.20) by ($0.10). As a group, equities analysts anticipate that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Investors Weigh In On NRx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in the business. AdvisorShares Investments LLC increased its stake in NRx Pharmaceuticals by 138.5% during the 4th quarter. AdvisorShares Investments LLC now owns 310,314 shares of the company’s stock worth $683,000 after buying an additional 180,229 shares during the period. Anson Funds Management LP increased its position in shares of NRx Pharmaceuticals by 30.3% in the 4th quarter. Anson Funds Management LP now owns 185,660 shares of the company’s stock valued at $408,000 after purchasing an additional 43,135 shares during the last quarter. Millennium Management LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $61,000. Squarepoint Ops LLC purchased a new stake in shares of NRx Pharmaceuticals in the 4th quarter valued at approximately $56,000. Finally, Townsquare Capital LLC purchased a new stake in shares of NRx Pharmaceuticals in the 3rd quarter valued at approximately $25,000. 4.27% of the stock is owned by hedge funds and other institutional investors.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc, a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior.